Analyst Ratings For Urogen Pharma (NASDAQ:URGN) (NASDAQ:URGN)
Today, Oppenheimer reiterated its Buy rating on Urogen Pharma (NASDAQ:URGN) (NASDAQ:URGN).
Some recent analyst ratings include
- 3/22/2018-Oppenheimer Reiterated Rating of Buy.
- 3/19/2018-Jefferies Group Reiterated Rating of Buy.
- 3/16/2018-Ladenburg Thalmann Financial Services Reiterated Rating of Buy .
- 11/15/2017-Cowen Reiterated Rating of Buy.
- 11/15/2017-CIBC Reiterated Rating of Outperform .
- 11/15/2017-Raymond James Financial was Downgraded by analysts at Raymond James Financial from a “Outperform ” rating to a ” Market Perform” rating.
- On 11/28/2017 Proquest Investments Iv, L.P., Major Shareholder, sold 209,298 with an average share price of $40.60 per share and the total transaction amounting to $8,497,498.80.
Recent Trading Activity for Urogen Pharma (NASDAQ:URGN) (NASDAQ:URGN)
Shares of Urogen Pharma (NASDAQ:URGN) closed the previous trading session at 54.60 up +0.84 1.56% with 51.13100051879883 shares trading hands.
